Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miyuru Amarapala

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Clinicoeconomics and Outcomes Research : CEOR|February 25, 2025
Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer PerspectiveChristian Siegfried, Miyuru Amarapala, Xavier Leleu, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersYan Helen Hu, Elizabeth Somers, Miyuru Amarapala, et al.
Journal of Medical Economics|January 17, 2022
Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspectiveAdrian Kilcoyne, Edward Jordan, Allen Zhou, et al.
Clinicoeconomics and Outcomes Research : CEOR|April 21, 2022
Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 (COVID-19) from the Perspective of National Health Service EnglandAdrian Kilcoyne, Edward Jordan, Kimberly Thomas, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 20, 2024
A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosisKian Jalaleddini, Robert A Bermel, Bari Talente, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Clinicoeconomics and Outcomes Research : CEOR|February 25, 2025
Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer PerspectiveChristian Siegfried, Miyuru Amarapala, Xavier Leleu, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersYan Helen Hu, Elizabeth Somers, Miyuru Amarapala, et al.
Journal of Medical Economics|January 17, 2022
Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspectiveAdrian Kilcoyne, Edward Jordan, Allen Zhou, et al.
Clinicoeconomics and Outcomes Research : CEOR|April 21, 2022
Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 (COVID-19) from the Perspective of National Health Service EnglandAdrian Kilcoyne, Edward Jordan, Kimberly Thomas, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 20, 2024
A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosisKian Jalaleddini, Robert A Bermel, Bari Talente, et al.
Pageof 1